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ABSTRACT 30 
The β-site APP Cleaving enzyme 1 (BACE1) is a membrane-associated aspartyl protease which 31 
mediates the production of amyloid-β (Aβ), a major component of amyloid plaques in the 32 
Alzheimer’s disease brain. We have synthesised and characterised a series of peptidomimetic 33 
analogues of BACE substrates that incorporate two distinct stabilising structures. To 34 
demonstrate the potential activity of these compounds, a variety of assaying strategies were 35 
used to investigate cleavage susceptibility and inhibition potency under competitive and non-36 
competitive conditions. β-Amino acids and scissile site N-methylation were incorporated into 37 
peptide substrate templates as transition state isostere (TSI) substitutes by positional 38 
scanning to generate series of non-TSI β-peptidomimetics. The amino acid sequences flanking 39 
the β-cleavage site within APP carrying the Swedish double mutation (APPSW), Neuregulin, the 40 
synthetic hydroxyethylene-based TSI peptide inhibitor OM99-2 and the high affinity peptide 41 
sequence SEISYEVEFR, served as the four substrate templates from which over 60 peptides 42 
were designed and synthesised by solid phase peptide synthesis. A Quenched Fluorescent 43 
Substrate BACE1 assay in conjunction with LC-MS analysis was established to investigate 44 
cleavage susceptibility and inhibition potency under competitive and non-competitive 45 
conditions. It was determined that β-amino acids substituted at the P1 scissile site position 46 
within known peptide substrates were resistant to proteolysis, and particular substitutions 47 
induced a concentration-dependent stimulation of BACE1, indicating a possible modulatory 48 
role of native BACE1 substrates.   49 
  50 
INTRODUCTION 51 
Beta-site APP Cleaving enzyme (BACE) is a membrane-associated enzyme involved in 52 
the production of amyloid-beta which is implicated in the formation of amyloid plaques within 53 
the Alzheimer’s disease brain. BACE performs the primary cleavage of Amyloid Precursor 54 
Protein (APP) and has been investigated as a possible therapeutic target [1-3] although clinical 55 
trials have demonstrated off-target effects [4-6]. For over a decade, the BACE drug landscape 56 
has grown steadily, from the identification of peptide substrates as functional templates and 57 
the rational design of peptidomimetic inhibitors to the acute analysis of BACE structural 58 
interactions and the development of potent, selective small molecule BACE inhibitors for the 59 
treatment of AD [5, 7-9]. A strict consensus sequence does not appear to be required for BACE 60 
substrate recognition or hydrolysis [10]. In addition, BACE is modulated by allosteric 61 
interaction and numerous post-translational modifications to the catalytic domain [11-13], 62 
and a range of substrates other than APP have been identified to interact with BACE, each 63 
with specific functional and modulatory roles in metabolism and  signalling [14-16]. Thus, an 64 
increased understanding of BACE modulation may be obtained by investigating the effects of 65 
the post-translational modifications on BACE activity and specificity. 66 
To date, many small molecule and peptidomimetic inhibitors that target the BACE 67 
active-site exhibit potent activity in vitro but fail to exhibit similar activity in whole cells or in 68 
vivo [5, 6, 17-19]. Additionally, peptides and polyglycan compounds that do not exclusively 69 
engage the transition-state but elicit a variety of modulatory effects have been synthesised 70 
[12, 20, 21]. 71 
The development of peptidomimetic BACE inhibitors frequently employs a rational 72 
design approach whereby compatible peptide substrates act as templates from which lead 73 
compounds are developed (Figure 1). Within BACE peptidomimetics, scissile-site residues are 74 
substituted for non-cleavable extended backbone structures, termed transition state 75 
isosteres (TSI), designed to mimic the high affinity transition-state as an inhibitory mechanism 76 
(Figure 1E). Many of the TSIs utilised in BACE inhibitor design are structurally similar to, or are 77 
derivatives of, β-amino acids. In addition, SAR-based studies are frequently used to 78 
investigate modifications to residues flanking the active-site to improve inhibitor specificity 79 
and potency. Due to the focus on the development of small molecule-based BACE inhibitors, 80 
there is very little information regarding the effect of peptidomimetic substrates containing 81 
an extended peptidomimetic backbone when not engaged in the transition-state. Given the 82 
varied efficacy of current inhibitors, in this study we have investigated peptidomimetic 83 
substrates which contain non-transition state β-amino acid analogues that are able to 84 
modulate BACE activity toward the APPSW substrate in vitro.  85 
The majority of BACE inhibitors implement P1-P1’ transition state mimetics in the form 86 
of hydroxyl carrying moieties and enzyme specificity and peptide solubility are modulated by 87 
changes in the residues flanking the scissile structure. While the presence of a hydroxyl group 88 
at the scissile site is required to mimic the transition state, the orientation and position with 89 
respect to the accompanying side chain are significant determinants of inhibitory function 90 
and potency. Structural and functional analysis has determined the positional offset provided 91 
by the extended β-amino acid-like carbon backbone of the hydroxyethyl- (HEA) and 92 
hydroxymethyl- (HMC) mimetics to be a critical determinant of inhibition potency when the 93 
transition state is presented [10, 22-24]. Thus, novel peptidomimetic structures which 94 
stabilise the scissile bond in a strong binding substrate may represent a viable approach to 95 
develop compounds to investigate BACE proteolytic activity. 96 
We therefore aimed to evaluate the effects of backbone modifications using N-97 
methylation and β-amino acid substitutions at the scissile site within known BACE substrates 98 
on BACE activity (Figure 1A, 1B). Undertaking a rational design approach, peptidomimetics 99 
incorporating β-amino acids were synthesised within the following four substrate templates: 100 
the β-cleavage site within APP carrying the Swedish double-mutation (APPSW), Neuregulin 101 
(NRG1), the synthetic hydroxyethylene-based TSI peptide inhibitor OM99-2 and the high 102 
affinity peptide sequence SEISYEVEFR (Figure 1D). In order to evaluate the peptidomimetics 103 
and monitor the effects on BACE activity, a quenched fluorescent substrate (QFS) biochemical 104 
competition assay and LC-MS time course analytical methods were developed. 105 
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FIGURE 1: BACE1 PEPTIDE SUBSTRATE TEMPLATES FOR PEPTIDOMIMETIC MODULATOR DESIGN 137 
 138 
A: APP domains and APPSW BACE cleavage site. B: BACE active site subsite alignment with 139 
template amino acid sequences utilised in this study. APPSW – 10 residue APP peptide 140 
incorporating the KM→NL Swedish double mutant [25], A10 – 10 residue synthetic peptide 141 
substrate containing the high affinity ISY-EV core [26], OM99-2PEP – 8 residue amino acid 142 
sequence from the OM99-2 hydroxyethylcarbonyl (statine) TSI [22], NRG1 – 10 residue human 143 
Neuregulin 1 Isoform 1 HRG β-1 derived peptide (GenBank NCBI Ref Seq: NP_039250.2). Blue 144 
arrow indicates the scissile site. Red box highlights ‘core’ P3-P2’ template residues. C: α-peptide 145 
structure scissile site residues in S1, S1’ pocket. D: Mimetic approaches employed in this study 146 
depicted in red, (1) - example of C2 β-amino acid substitution, introduction of β-carbon 147 
backbone bond with respect to α-amino acid (2) – N-methylation of scissile site amide bond. E: 148 
Example structure of a transition state isostere, Hydroxyethylene (HE) inhibitor. 149 
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 156 
Peptide Design 157 
 158 
The common structural element of HEA and HMC mimetics that provides the 159 
preferred extended carbon backbone is the presence of a scissile site β-amino acid. β-amino 160 
acids are both naturally occurring and synthetically engineered arrangements which elicit 161 
unique properties on many peptide substrates and proteins [27-29]. β-amino acids differ from 162 
their α-amino acid counterparts by the addition of a β-carbon group. The extended backbone 163 
allows for additional side chain stereochemistry comprised of four possible isomers for each 164 
α-amino acid and two possible R-group conformations on the C2 (Cα) and C3 (Cβ) carbon. 165 
Considering the HEA and HMC β-amino acid equivalents, interaction with BACE occurs within 166 
the S1 subsite pocket if incorporated within the substrate at P1, while the adjacent structure 167 
of the HEA at P1’ fills the S1’ subsite. HMCs which contain a hydroxyl β-amino acid, occupy the 168 
P1 position alone. 169 
A series of peptidomimetics were thus generated from the peptide substrates 170 
described in Figure 1 in order to investigate the effects of non-transition state β-171 
peptidomimetics on BACE activity. The α-peptide templates represent a range of reported 172 
substrates of varying sequence and function in order to identify specific effects imposed by 173 
each substitution. Firstly, the APP peptide containing the Swedish double mutant (APPSW) was 174 
selected to represent endogenous APP as observed in familial AD models [25], and as a control 175 
for the APPSW QFS substrate utilised within the rhBACE modulation assay and which also 176 
contains this core sequence. The A10 substrate was equivalent to the 10-mer peptide 177 
containing the high affinity ISY-EV core identified by Tomasselli et al. [26]. The A9 and A15 178 
templates were derived from the A10 peptide – the C-terminal Arg was omitted in A9, while 179 
A15 contains a 5 amino-acid N-terminal extension respectively. The OM99-2PEP template 180 
represents the 8 amino acid only sequence of the OM99-2 statin transition state inhibitor in 181 
which the P1-P1’ statin Leu*Ala isostere is replaced with their corresponding α-amino acids 182 
[22]. Finally, the NRG1 template is the 10-mer peptide sequence flanking the BACE cleavage 183 
site identified within the Neuregulin 1 Isoform 1 HRG β-1 protein [14, 30](GenBank NCBI Ref 184 
Seq: NP_039250.2). 185 
Initially, the turnover rate of each substrate template was evaluated and compared to 186 
the QFS reference substrate, which included the effects of termini neutralisation by N-187 
terminal acetylation and C-terminal amidation. Additionally, scissile site N-methylation was 188 
also evaluated to determine whether any effects by β-amino acid substitutions would be 189 
observed due to the backbone extension or the inability of BACE to cleave the substrate.   190 
 191 
SUBSTRATE TEMPLATE ANALYSIS  192 
The peptide templates and peptidomimetics in this study were synthesised by solid phase 193 
synthesis followed by reversed-phase HPLC purification. Nine series of peptides were 194 
synthesised the peptide sequence, molecular weight, RP-HPLC purification retention time and 195 
MS target mass are listed in Table 1. The majority of peptides were insoluble at 196 
concentrations greater that 50 μM (10 μM final) even when solubilised in 12.5 % DMSO (2.5% 197 
final in assay buffer). For this reason, peptide screening was performed at a maximum final 198 
concentration of 10 μM. Conversely, at peptide screening concentrations less than 0.1 μM, 199 
minimal effects on rhBACE activity were observed. Therefore, for comparative measures all 200 
peptides were screened utilising the rhBACE modulation assay at 10, 1 and 0.1 μM 201 
concentrations.  202 
 203 
Effect of Termini Capping upon Substrate Template Turnover 204 
 205 
 As a preliminary analysis of the substrate characteristics of the parent peptide 206 
templates (Series 1, Table 1), each peptide was analysed using the rhBACE LC-MS time-course 207 
assay under non-competitive conditions to determine the turnover rates as a percentage 208 
relative to that of the QFSAPP (Figure S1). This assay measured the rate of formation of the N-209 
terminal cleavage product, and of the four peptides that contain the APPSW sequence, only 210 
the N- and C-terminally capped peptide (Ac-APPSW10-Am) exhibited a high level of proteolysis 211 
(Figure S2). In addition, the N- and C-terminally capped analogues Ac-A10-Am, Ac-OM992pep-212 
Am and Ac-NRG1-Am were all cleaved to a greater extent than the uncapped parent A10, 213 
OM992pep and NRG1 peptides (Figure S2), with Ac-A10-Am exhibiting the highest rate of 214 
cleavage. 215 
 216 
P1-P1’ Scissile Site N-methylation 217 
 218 
Peptide Cleavage Analysis 219 
 220 
 Series 2 peptides were N-methylated at the scissile bond (Table 1) and were subject 221 
to the rhBACE LC-MS time course assay under non-competitive conditions. All scissile site N-222 
methylated substrates were resistant to rhBACE proteolysis with a typical LC-MS analysis 223 
shown for the A10 peptides shown in Figure S3 revealing the production of the expected 224 
cleavage fragments. In addition, when an equimolar amount of each peptide was incubated 225 
with the corresponding N-methyl analogue, there was an approximately 50% decrease in the 226 
rate of cleavage (Figure S3A and Figure S3C). These results indicated that the N-methylated 227 
BACE substrates retained the BACE binding characteristics of the un-methylated peptide 228 
analogues.  229 
 230 
Effects of Capping & Scissile Site N-methylation of Substrates upon rhBACE1 Activity 231 
 232 
 The Series 1 & 2 template peptides (uncapped, capped, N-methylated and non-N-233 
methylated) were then subjected to the rhBACE modulation assay under competitive 234 
conditions (Figure 2) followed by peptide cleavage analysis (Figure S4). The C-terminal P5’ 235 
arginine within the A10 substrate does not strictly occupy a sub-site within the BACE active 236 
site cleft and therefore an A9 truncated peptide was included to identify any redundancy. The 237 
A10 and A9 peptides induced similar effects on rhBACE activity (Figure 2A, blue, orange lines). 238 
While all peptides were designed to bind to the active site of BACE and act as competitive 239 
inhibitors, both inhibitory and stimulatory activity was observed. For example, un-capped A10 240 
and A9 peptides showed little effect at lower concentrations but induced significant 241 
stimulation at 10 μM. In contrast, capped A10 and A9 demonstrated moderate inhibition at 242 
low concentrations but were ineffective at high concentration (Figure 2B). By comparison, the 243 
uncapped and capped NRG peptides inhibited at lower concentration, with no observed effect 244 
when capped (Figure 2A & 2B, purple lines). The OM99-2PEP substrate was ineffective when 245 
capped, yet mildly inhibitory QFS processing when capped (Figure 2A & 2B, red lines).  246 
N-Methylated un-capped substrates exhibited very little inhibitory activity (Figure 2 247 
C), despite competing with their non-methylated analogues (Figure S4). Amidation and 248 
acetylation of the N-methylated A10 substrate had no effect on QFS turnover (Figure 2D, blue 249 
line), whereas NRG1 elicited stimulatory activity at high concentrations (Figure 2D, purple 250 
line) and the OM99-2PEP substrate moderately inhibited QFS processing at 1 and 0.1 μM 251 
(Figure 2D, red line).252 
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FIGURE 2: EFFECT OF CAPPING & SCISSILE-SITE N-METHYLATION ON RHBACE1 ACTIVITY 
 
Activity analysis by rhBACE QFSAPP modulation assay of peptide templates with or without capping and N-
methlyation. A: Uncapped peptides. B: Capped peptides. C: Uncapped N-methylated. D: Capped N-
methylated. Assays performed utilising rhBACE under standard conditions. Activities are expressed as the 
change in rate of QFS turnover as a percentage of the QFS control. See Table 1 – Series 1 & 2 for peptide 
sequences. 
 ANALYSIS OF β-AMINO ACID P1 & P1’ SCISSILE SITE SUBSTITUTIONS 262 
 263 
Cleavage Analysis of Peptides with Homologous β-Amino Acid P1 Scissile Site Substitutions 264 
 265 
 Series 3, 5 and 6 peptides contained P1 β-amino acid substitutions at the scissile bond 266 
(Table 1) and were screened for susceptibility to proteolysis. All scissile site P1 β-amino acid 267 
substituted peptides were resistant to proteolysis by BACE for the duration of the time-course. 268 
A typical analysis by LC-MS failed to detect cleavage products apart from those that resulted 269 
from the QFS from the A9, OM99-2PEP and NRG1 β-peptides (Figure S5). 270 
 271 
Effects of β-Amino Acid P1 and P1’ Scissile Site Substitutions upon rhBACE1 Activity 272 
 273 
 The effects of β-amino acids on BACE inhibition of the Series 3 peptides were first 274 
investigated using the rhBACE modulation assay. These peptides contained scissile bond 275 
substitution with either the β-homologues, β-glycine or β-alanine (h-G-A) substitutions at the 276 
P1 scissile site to un-capped A9, OM99-2PEP and NRG1 peptides (Table 1), and none of these 277 
peptides exhibited inhibitory activity but did show varying degrees of rhBACE stimulation 278 
(Figure 3). The β-homologue NRG1-P1βF peptide induced a potent stimulatory effect at 10 μM 279 
with a 1.8-fold increase in the rate of fluorescence (Figure 3A, purple line). Interestingly, the 280 
parent NRG1 peptide containing the wild-type -Phe amino acid inhibited QFS cleavage at 281 
moderate and low concentrations (Figure 3A, purple line). Stimulation at 10 μM was also 282 
observed for the βG and βA heterologues of A9 and OM99-2PEP peptides (Figure 3A, blue, red 283 
lines), while homologous substitutions to these scaffolds had no observable effects (Figure 284 
3A). 285 
h-G-A β-substitutions were also introduced to the A9 P1’ scissile (Series 4, Table 1) and 286 
the P1 site within the A5 peptide (a truncated core sequence – ISY-EV) (Series 5, Table 1, Figure 287 
4A & 4C) to investigate the effect of β-amino acids on scissile site preference and peptide 288 
length within the A9 substrate. The results are compared with A9 P1 site substitutions (Figure 289 
4B). The βE and βG P1’ substitutions (Figure 4A, red, blue) resulted in increased stimulation 290 
compared to the corresponding substitutions at the P1 position (Figure 4D, blue & Figure 4B, 291 
red). The A9-P1’βG peptide resulted in a 5-fold and 2.5-fold increase in stimulation at 10 and 1 292 
μM respectively. The mild stimulation that resulted from the A9-P1βA (Figure 4B, purple) was 293 
inhibitory to rhBACE activity for A9-P1’βA in excess of 70% at 10 μM (Figures 4A & 4B, purple 294 
lines). rhBACE was inhibited by the truncated A5 core sequence P1 β-peptides at all 295 
 concentrations with the exception of βG at 10 μM (Figure 4C). Overall, side-chain removal at 296 
the P1 or P1’ site by βG-substitution elicited stimulation at 10 μM (Figures 4A,B,C, red lines). 297 
 298 
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FIGURE 3: EFFECT OF β-AMINO ACID P1 SCISSILE-SITE SUBSTITUTIONS ON RHBACE1 ACTIVITY 312 
 313 
Activity by rhBACE QFSAPP modulation assay of P1 β-amino acid substitutions within 314 
peptide templates. A: Homologue substitutions. B: Glycine substitutions. C: Alanine 315 
substitutions. Assays were performed utilising rhBACE under standard conditions. 316 
Activities are expressed as the change in rate of QFS turnover as a percentage of the 317 
QFS control. See Table 1 – Series 3 for peptide sequences. 318 
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   321 
Additional A9 P1 β-substituted peptides (Series 6, Table 1) were evaluated to identify 322 
influences of side-chain type and charge (Figure 4 D,E,F). Each β-amino acid substitution 323 
resulted in a unique modulatory profile. Most notably, β-Pro stimulated the baseline QFSAPP 324 
cleavage rate by 500% at 10 μM and inhibited the baseline activity by 25% at 0.1 μM (Figure 325 
4F, red). The hydrophobic β-Val and β-IIe residues stimulated rhBACE over a 1-10 μM range, 326 
however, the β-Leu residue inhibited activity only, indicating a preference for side-chain 327 
orientation at the P1 site (Figure 4E). 328 
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 337 
FIGURE 4: EFFECTS OF P1-P1’ β-AMINO ACID SCISSILE-SITE SUBSTITUTIONS IN THE A9 SUBSTRATE ON RHBACE1 ACTIVITY 338 
 339 
Activity analysis by rhBACE QFSAPP modulation assay of P1 & P1’ β-amino acid substitutions within the A9 peptide template. A: P1’ substitutions. B: P1 340 
substitutions (Group 1). C: P1 substitutions (Group 1) 5-mer truncated peptide. D: P1 substitutions (Group 2). E: P1 substitutions (Group 3). F: P1 341 
substitutions (Group 4). Assays were performed utilising rhBACE under standard conditions. Activities are expressed as the change in rate of QFS 342 
turnover as a percentage of the QFS control. See Table 1 – Series 5 & 6 for peptide sequences. 343 
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ANALYSIS OF AMINO ACID SUBSTITUTIONS N-TERMINAL TO THE SCISSILE SITE 344 
 345 
Effects of Upstream -Alanine Substitutions of A10, A15 Substrates upon rhBACE1 Activity 346 
 347 
 In order to investigate the high turnover observed within the capped A10 substrate, 348 
peptides incorporating an -alanine substitution upstream of the scissile site were 349 
synthesised (Series 7, Table 1) and subject to the rhBACE modulation assay. With the 350 
exception of P3Ala, QFS turnover was mildly inhibited within a 10 per cent margin for all of 351 
the Ala substituted A10 peptides over the concentration range tested (Figure 5A). The 352 
P3Ala substitution was 30 per cent more inhibitory at 0.1 μM compared to 10 μM which had 353 
no effect on QFS turnover rates (Figure 5A, purple).  354 
The A15 capped peptide, incorporating five additional APP N-terminal sequence 355 
amino acids, was also synthesised. In addition, two A15 variants carrying -alanine 356 
substitutions for the P7 and P8 glutamate residues were synthesised (Series 8, Table 1). 357 
Removal of the negatively charged glutamates for the hydrophobic methyl group of the 358 
alanine resulted in a similar rhBACE modulation profile compared to the A15 template 359 
peptide (Figure 5B) and the A10 P3Ala substitution. The upstream negative charges within 360 
the capped peptides did not contribute significantly to modulation of the rhBACE enzyme, 361 
although a mild increase in stimulation was noted at 10 μM for each Ala substitution (Figure 362 
5B, purple & red) compared to the A15 template (Figure 5B, blue). 363 
  364 
 15 
 365 
 366 
 367 
 368 
 369 
 370 
FIGURE 5: EFFECT OF UPSTREAM -ALA SUBSTITUTIONS ON RHBACE1 ACTIVITY 371 
Activity analysis of upstream -Ala substitutions within the A10 & A15 peptide template by rhBACE 372 
QFSAPP modulation assay. A: P5-P1 ala substitutions within the capped A10 template. B: P7,P8 ala 373 
substitutions within the capped A15 extended template. Assays performed utilising rhBACE under 374 
standard conditions. Activities are expressed as the change in rate of QFS turnover as a percentage of 375 
the QFS control. See Table 1 – Series 7 & 8 for peptide sequences. 376 
 377 
Cleavage Analysis of Upstream β-Amino Acid Substitutions within the A9 Substrate 378 
 379 
 The susceptibility to BACE cleavage of the A9 peptides containing upstream β-amino 380 
acid substitutions (Series 8, Table 1) was analysed using the rhBACE1 LC-MS time-course assay 381 
under QFSAPP competitive conditions (Figure 6). All A9 β-peptides carrying h-G-A substitutions 382 
upstream of the P2 site were cleaved by rhBACE and the product turnover cleavage rates 383 
increased with distance away from the scissile site at which the β-substitutions were placed 384 
(Figure 6). Homologous substitutions were cleaved more readily than the corresponding βG 385 
and βA substitutions. Of note, the A9-P4βE peptide exhibited the highest rate of turnover - a 386 
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rate marginally greater than the parent -A9 template. Substitutions made to the P2 site 387 
retained the proteolytic resistance observed in the P1 and P1’ substituted peptides, regardless 388 
of the β-amino acid type (Figure 6). 389 
 390 
Effects of Upstream β-Amino Acid Substitutions of A9 Substrates upon rhBACE1 Activity 391 
 392 
 h-G-A β-amino acid substituted peptides at the P5-P2 position induced stimulation at 393 
high concentrations and inhibition at low concentrations (Figure 7), as observed previously in 394 
P1 β-substituted peptides (Figure 4A). While both A9 P1 and P2 β-substituted peptides resisted 395 
proteolysis, substitutions at the P2 position elicited a greater stimulatory effect on QFS 396 
turnover (Figure 7 D). Interestingly, proteolysis rates of both the A9-P4βE peptide (Figure 7 B, 397 
blue) and the competing QFSAPP substrate were greater than that of the corresponding 398 
turnover rates of wild-type A9 peptide (Figure 2B, orange) and QFSAPP under competitive 399 
conditions. 400 
 401 
 402 
  403 
 404 
 405 
 406 
FIGURE 6: EFFECT OF UPSTREAM P5-P2 β-AMINO ACID SUBSTITUTIONS ON SUBSTRATE TURNOVER 407 
 408 
Product turnover analysis of P5-P2 homologous, Gly & Ala β-amino acid substitutions 409 
within the A9 peptide template. Rates of N-terminal product turnover were 410 
determined by LC-MS time-course. Error between replicates was negligible. All assays 411 
were performed utilising rhBACE with 10 M peptide. Product turnover is expressed 412 
as a percentage of the determined QFSAPP rate (100%). See Table 1 – Series 9 for 413 
peptide sequences. 414 
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 415 
 416 
  417 
 418 
 419 
  420 
 421 
FIGURE 7: EFFECT OF UPSTREAM P5-P2 β-AMINO ACID SUBSTITUTIONS ON RHBACE1 ACTIVITY 422 
 423 
Activity analysis by rhBACE QFSAPP modulation assay of P5-P2 homologous, Gly & Ala β-amino acid 424 
substitutions within the A9 peptide template. A: P5 substitutions. B: P4 substitutions. C: P3 substitutions. 425 
D: P2 substitutions. All assays were performed utilising rhBACE under standard conditions. Activities are 426 
expressed as the change in rate of QFS turnover as a percentage of the QFS control.  See Table 1 – Series 427 
9 for peptide sequences.428 
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DISCUSSION 429 
β-Amino acids are mimetic structures of their α-amino acid counterparts and have 430 
been used as a mimetic to stabilise a range of peptide scissile bonds. [27-29]. The use of β-431 
peptides to inhibit enzymatic proteolysis has been previously demonstrated by studies using 432 
β-hydroxy amino acids in the form of transition state HEA and HMC peptidomimetics against 433 
and BACE [31, 32]. Additionally, β-peptides which do not contain a transition state mimetic 434 
are also effective inhibitors of a range of enzymatic targets [33-35]. One notable advantage 435 
of utilising β-amino acids is that they may be incorporated into peptide-based structures by 436 
standard peptide synthesis techniques. The aim of this study was to evaluate the use of β-437 
amino acids in place of currently utilised TSI mimetics for BACE inhibition. It was hypothesised 438 
that a β-amino acid substitution at the scissile site would provide the extended carbon 439 
backbone of the HEA and HMC moieties and would compete with the reference QFS substrate 440 
for the BACE active site. Thus, a kinetic model typical of competitive inhibition was expected, 441 
ie: cleavage of one substrate would be inhibited by an increase in concentration of the other, 442 
and conversely, turnover of a competing substrate would be increased with a decrease in 443 
concentration of the other as competition for the active site is reduced. Thus far, BACE active-444 
site inhibitors reported in the current literature compete for the active site in this manner to 445 
inhibit proteolysis.  446 
 The results presented here indicate that the substrate templates and peptidomimetic 447 
structures within this study may not exclusively interact with the active-site. Instead, 448 
modulatory kinetics profiles were observed whereby the rate of QFS APPSW substrate 449 
cleavage was stimulated or inhibited by BACE, dependant on the concentration and mimetic 450 
substitution of the competing test peptides. In order to quantify the apparent bimodal 451 
kinetics, a time course study was performed and the products analysed by LC-MS. In this 452 
manner, the products of cleavage were quantified in which the extent of QFS turnover was 453 
used as a relative measurement of BACE inhibition or stimulation to establish standardised 454 
modulatory profiles. Modulators of BACE activity were identified based on stimulatory and 455 
inhibitory effects monitored by the change in rate of QFS APPSW turnover. When coupled with 456 
LC-MS analysis, substrate cleavage products were quantified which provided further insight 457 
into the mechanism of peptidomimetic induced BACE modulation.  458 
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The A10 and NRG1 displayed inconsistent stimulatory and inhibitory effects upon QFS 459 
turnover which was dependent on the type of modification. This was in contrast to the 460 
inhibitory effects observed on substrate turnover under competitive conditions by N-methyl 461 
and parent peptide mixtures. QFS turnover was not stimulated by the OM99-2PEP substrate, 462 
which acted as a mild inhibitor when capped, irrespective of termini capping and N-463 
methylation.  464 
 Stimulation was mitigated by the capped A10/A9 peptides despite their higher 465 
turnover rate compared to the uncapped variants. With the exception of NRG1, mild BACE 466 
inhibition at mid- to low-range concentrations by capped peptides suggests an increased 467 
affinity for the BACE active site in agreement with the noted increased turnover. In contrast, 468 
QFS turnover was neither stimulated nor inhibited by N-methylation at the scissile site within 469 
uncapped peptides, however in capped peptides, sequence dependant inhibition and 470 
stimulation was observed even though cleavage analysis indicated N-methylation of the 471 
scissile site rendered these peptides uncleavable. Unlike N-methylation, the structure of the 472 
peptide bond is maintained by substituted β-amino acids. As observed in HEA and HMC TSIs, 473 
the displacement imposed by the β-carbon within the P1 backbone is accommodated by the 474 
active-site. Regardless of side chain, P1 substituted β-peptides were resistant to proteolysis 475 
and displayed significant concentration dependant modulatory profiles which indicated the 476 
potent inhibition observed by TSI peptidomimetics was heavily reliant upon the presence of 477 
the hydroxyl intermediate and its coordination between the aspartates and the flap region 478 
during interaction with the active site S1 and S1’ sub-sites. 479 
N-terminal to the scissile-site, the proteolytic resistance conferred by β-substitution 480 
was dependent on engaging the S1 sub-site. β-Substitution upstream of P1 or P1’ resulted in 481 
concomitant increase in β-peptide turnover, yet all β-substitutions modulated QFS turnover 482 
differentially from the α-alanine substituted peptides which were largely inhibitory. Overall, 483 
these results demonstrate the ability of β-peptides to both stimulate and inhibit BACE activity 484 
which suggests different binding sites may exist within BACE. It has also been observed that 485 
that some compounds can stimulate BACE by relieving steric hindrance at the active site 486 
caused by the pro-domain and commercial preparations of BACE1 contain a large proportion 487 
of proenzyme [11, 12, 36, 37]. Since it is likely that inhibition occurs via interaction within the 488 
defined active site, while stimulation occurs allosterically, the introduction of β-amino acids 489 
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at defined positions within the template sequences and the local concentration clearly affect 490 
the binding mode type and modulation potency. 491 
In summary, a series of peptidomimetic BACE substrates were synthesised and their 492 
effects as modulators of BACE1 activity were investigated. Unexpectedly, the substitution of 493 
scissile site residues with β-amino acids identified unique modulatory profiles. From these 494 
results, a dual binding model can be considered whereby at low concentrations, the 495 
peptidomimetics engage the active site, and at high concentrations, they interact with BACE1 496 
either allosterically or via effects on the pro-domain. Though preliminary, these observations 497 
represent primary evidence to suggest BACE activity may be regulated allosterically by its own 498 
active-site substrates. 499 
 500 
CONCLUSION 501 
 The use of β-amino acids has played a diverse role in peptidomimetic drug design for 502 
numerous targets, particularly for BACE1, in the form of TSI analogues which have been 503 
readily developed as high affinity active site inhibitors. P1 β-peptidomimetics in this study 504 
which did not present a transition state analogue structure were found to be uncleavable, yet 505 
induced significant BACE modulation. Besides concentration, the magnitude of modulation 506 
was influenced by the particular β-amino acid side chain charge and structure, differentially 507 
from active site subsite preferences at the corresponding P1 position. These results identified 508 
a novel influence upon BACE1 modulation, in addition to known structural and environmental 509 
factors. 510 
 511 
  512 
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EXPERIMENTAL 513 
Peptide Synthesis 514 
 Peptides were synthesised utilising established SPPS methods [Supplementary 515 
Information]. Wang and Rink-amide AM resins were used for C-terminal carboxylic acid and 516 
amide moieties respectively. Fmoc-deprotection, amino acid activation and coupling steps 517 
were cycled to N-terminally extend the peptide sequence. N-methylation was performed 518 
following deprotection of the required residue C-terminal to the N-methylation site, followed 519 
by subsequent coupling. The required peptides were N-terminally acetylated following the 520 
final deprotection of a completed peptide sequence. Kaiser tests and acetyl-capping 521 
procedures were performed at various stages to troubleshoot specific syntheses and 522 
maximise target peptide yield. Following synthesis, peptides were cleaved from the resin and 523 
side chains deprotected. Crude peptides were then isolated from the resin, lyophylised and 524 
the target peptide identified by MS. Crude peptide containing minimal deletion products and 525 
a sufficient yield of target were deemed fit for RP-HPLC purification. 526 
 527 
RHBACE1 Modulation Assays 528 
 529 
QFS Cleavage As a Relative Measure of rhBACE Activity 530 
 531 
Peptides (10 μM) were subject to the QFSAPP rhBACE1 modulation assay under 532 
standard conditions. Reaction rate was determined for each assay triplicate and an average 533 
rate and standard deviation was calculated. Rate of QFS cleavage was then expressed as a 534 
change in rate, as a %, with respect to the control QFS cleavage rate as follows:  535 
 536 
𝛥 𝑅𝑎𝑡𝑒 (%) =   (
𝑟𝑎𝑡𝑒(𝑄𝐹𝑆+𝑝𝑒𝑝𝑡𝑖𝑑𝑒) (𝐹𝑈/𝑚𝑖𝑛)
𝑟𝑎𝑡𝑒𝑄𝐹𝑆 (𝐹𝑈/𝑚𝑖𝑛)
× 100) − 100 537 
 538 
 539 
The QFS control rate is observed as the zero baseline. Values less than the QFS control 540 
rate - a reduction in the rate of QFSAPP turnover - observed as negative values, were deemed 541 
as inhibition. Rates in excess of the baseline rate - an increase in the rate of QFSAPP turnover - 542 
observed as positive values, were deemed as stimulatory. 543 
 544 
 545 
 546 
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Cleavage Product Analysis by Gradient LC-MS 547 
 548 
Peptides (10 μM) were subject to the QFSAPP rhBACE modulation assay under standard 549 
conditions. Following incubation, an equal volume (100 μL) of 10 % TFA in assay buffer was 550 
immediately administered to quench the remaining rhBACE activity. The sample was analysed 551 
by microflow-capillary gradient LC-MS utilising a Zorbax SD C-18 reverse-phase column. Prior 552 
to injection, samples were diluted 2-fold in 50 % MeOH / 0.1 % FA / H2O (10 μL). 553 
 554 
Samples were introduced to the column at a constant 5 % Buffer B for 20 min to 555 
minimise DMSO detector saturation/tailing effects. Following sample loading, separation was 556 
initiated and performed over a 5-85 % Buffer B gradient over 60 mins at a 15 µL/min flow-557 
rate with detection wavelengths set to 215/280 nm. Mass spectra were acquired via ESI-MS 558 
over the entire 90 min gradient over a 100-2,000 mass/charge (m/z) scan range in positive ion 559 
mode with a capillary voltage of 3,000 V. Target mass/charge ratio (500 m/z), accumulation 560 
time (200 ms), trap-drive level (70 %) and compound stability (30 %) settings were maintained 561 
for all data acquisition. The chromatogram absorbance peaks were identified by TIC-MS 562 
analysis. 563 
 564 
Cleavage Product Rate Determination by Gradient LC-MS Time-Course 565 
 566 
Initially, peptide turnover was determined by rhBACE assay over a time-course (0, 1, 567 
10, 15, 30, 60 and 180 min) for the A10 peptide. Assays were performed in the absence of the 568 
QFSAPP to enable relative turnover measurements to be determined. As the majority of C-569 
terminal products eluted within the tailing DMSO injection peak and were difficult to quantify, 570 
the kinetics derived from N-terminal product formation were a more reliable relative 571 
indicator for the rate of substrate cleavage. LC-MS was then performed for each time-point. 572 
The identified chromatographic absorbance peaks (Abs: 215 nm) were integrated 573 
(mAU2) and plotted. As the turnover of N-terminal product remained within the steady state 574 
within the first 30 mins, all subsequent time courses were performed for 0, 15 and 30 mins 575 
time-points only and linearly extrapolated. In addition, a reference peak area absorbance was 576 
determined by complete cleavage of the same peptide achieved by overnight incubation. The 577 
rate at which product was formed over time was determined from the integrated peak 578 
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absorbance at 30 mins during the steady-state (linear) phase expressed as a percentage of 579 
the total integrated peak absorbance following complete cleavage of the peptide as follows:  580 
 𝑅𝑎𝑡𝑒 (%) =  
𝑎𝑏𝑠𝑠𝑡𝑒𝑎𝑑𝑦−𝑠𝑡𝑎𝑡𝑒 (30 𝑚𝑖𝑛) (𝑚𝐴𝑈
2)
30 𝑥 𝑎𝑏𝑠𝑐𝑜𝑚𝑝𝑙𝑒𝑡𝑒 𝑐𝑙𝑒𝑎𝑣𝑎𝑔𝑒  (𝑚𝐴𝑈2)
× 100 581 
 582 
This value was converted to a relative percentage with respect to the QFS turnover reference 583 
rate normalised to 100 % according to:  584 
𝐁   𝑅𝑒𝑙𝑎𝑡𝑖𝑣𝑒 𝑅𝑎𝑡𝑒 (%) =   
𝑟𝑎𝑡𝑒𝑝𝑒𝑝𝑡𝑖𝑑𝑒  (%)
𝑟𝑎𝑡𝑒𝑄𝐹𝑆 (%)
× 100 585 
 586 
 587 
 588 
ACKNOWLEDGEMENTS 589 
MIA would like to pay tribute to her teacher, friend and colleague Professor Paul Alewood for 590 
his on-going support and encouragement throughout her career in peptide science. The 591 
authors wish to acknowledge the support of the Mason Foundation (ID 12112). 592 
 593 
CONFLICT OF INTEREST DECLARATION 594 
The authors declare no conflicts of interest. 595 
  596 
 24 
REFERENCES 597 
[1] R. Vassar, B.D. Bennett, S. Babu-Khan, S. Kahn, E.A. Mendiaz, P. Denis, D.B. Teplow, S. Ross, 598 
P. Amarante, R. Loeloff, Y. Luo, S. Fisher, J. Fuller, S. Edenson, J. Lile, M.A. Jarosinski, A.L. 599 
Biere, E. Curran, T. Burgess, J.C. Louis, F. Collins, J. Treanor, G. Rogers, M. Citron, Beta-600 
secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane 601 
aspartic protease BACE, Science 286 (1999) 735-41. 602 
[2] A.K. Ghosh, L. Hong, J. Tang, Beta-secretase as a therapeutic target for inhibitor drugs, Curr 603 
Med Chem 9 (2002) 1135-44. 604 
[3] J. Hardy, D.J. Selkoe, The amyloid hypothesis of Alzheimer's disease: progress and 605 
problems on the road to therapeutics, Science 297 (2002) 353-6. 606 
[4] D.S. Knopman, Bad news and good news in AD, and how to reconcile them, Nat Rev Neurol 607 
15 (2019) 61-62. 608 
[5] N.M. Moussa-Pacha, S.M. Abdin, H.A. Omar, H. Alniss, T.H. Al-Tel, BACE1 inhibitors: 609 
Current status and future directions in treating Alzheimer's disease, Med Res Rev  610 
(2019). 611 
[6] D. Selkoe, beta-secretase inhibitors for Alzheimer's disease: heading in the wrong 612 
direction?, Lancet Neurol 18 (2019) 624-626. 613 
[7] W.H. Huang, R. Sheng, Y.Z. Hu, Progress in the development of nonpeptidomimetic BACE 614 
1 inhibitors for Alzheimer's disease, Curr Med Chem 16 (2009) 1806-20. 615 
[8] A.K. Ghosh, H.L. Osswald, BACE1 (beta-secretase) inhibitors for the treatment of 616 
Alzheimer's disease, Chem Soc Rev 43 (2014) 6765-813. 617 
[9] I. Ponzoni, V. Sebastian-Perez, M.J. Martinez, C. Roca, C. De la Cruz Perez, F. Cravero, G.E. 618 
Vazquez, J.A. Paez, M.F. Diaz, N.E. Campillo, QSAR Classification Models for Predicting 619 
the Activity of Inhibitors of Beta-Secretase (BACE1) Associated with Alzheimer's Disease, 620 
Sci Rep 9 (2019) 9102. 621 
[10] R.T. Turner, 3rd, G. Koelsch, L. Hong, P. Castanheira, J. Ermolieff, A.K. Ghosh, J. Tang, 622 
Subsite specificity of memapsin 2 (beta-secretase): implications for inhibitor design, 623 
Biochemistry 40 (2001) 10001-6. 624 
[11] D. Klaver, A.C. Hung, R. Gasperini, L. Foa, M.I. Aguilar, D.H. Small, Effect of heparin on 625 
APP metabolism and Abeta production in cortical neurons, Neurodegener Dis 7 (2010) 626 
187-9. 627 
[12] D.W. Klaver, M.C. Wilce, R. Gasperini, C. Freeman, J.P. Juliano, C. Parish, L. Foa, M.I. 628 
Aguilar, D.H. Small, Glycosaminoglycan-induced activation of the beta-secretase 629 
(BACE1) of Alzheimer's disease, J Neurochem 112 (2010) 1552-61. 630 
[13] W. Wang, Y. Liu, R.A. Lazarus, Allosteric inhibition of BACE1 by an exosite-binding 631 
antibody, Curr Opin Struct Biol 23 (2013) 797-805. 632 
[14] X. Hu, C.W. Hicks, W. He, P. Wong, W.B. Macklin, B.D. Trapp, R. Yan, Bace1 modulates 633 
myelination in the central and peripheral nervous system, Nat Neurosci 9 (2006) 1520-634 
5. 635 
 25 
[15] S. Ben Halima, S. Mishra, K.M.P. Raja, M. Willem, A. Baici, K. Simons, O. Brustle, P. Koch, 636 
C. Haass, A. Caflisch, L. Rajendran, Specific Inhibition of beta-Secretase Processing of the 637 
Alzheimer Disease Amyloid Precursor Protein, Cell Rep 14 (2016) 2127-2141. 638 
[16] M. Pigoni, J. Wanngren, P.H. Kuhn, K.M. Munro, J.M. Gunnersen, H. Takeshima, R. 639 
Feederle, I. Voytyuk, B. De Strooper, M.D. Levasseur, B.J. Hrupka, S.A. Muller, S.F. 640 
Lichtenthaler, Seizure protein 6 and its homolog seizure 6-like protein are physiological 641 
substrates of BACE1 in neurons, Mol Neurodegener 11 (2016) 67. 642 
[17] I. Hussain, J. Hawkins, D. Harrison, C. Hille, G. Wayne, L. Cutler, T. Buck, D. Walter, E. 643 
Demont, C. Howes, A. Naylor, P. Jeffrey, M.I. Gonzalez, C. Dingwall, A. Michel, S. 644 
Redshaw, J.B. Davis, Oral administration of a potent and selective non-peptidic BACE-1 645 
inhibitor decreases beta-cleavage of amyloid precursor protein and amyloid-beta 646 
production in vivo, J Neurochem 100 (2007) 802-9. 647 
[18] J. Lamar, J. Hu, A.B. Bueno, H.C. Yang, D. Guo, J.D. Copp, J. McGee, B. Gitter, D. Timm, P. 648 
May, J. McCarthy, S.H. Chen, Phe*-Ala-based pentapeptide mimetics are BACE 649 
inhibitors: P2 and P3 SAR, Bioorg Med Chem Lett 14 (2004) 239-43. 650 
[19] H. Yamakawa, S. Yagishita, E. Futai, S. Ishiura, beta-Secretase inhibitor potency is 651 
decreased by aberrant beta-cleavage location of the "Swedish mutant" amyloid 652 
precursor protein, J Biol Chem 285 (2010) 1634-42. 653 
[20] S. Sinha, J.P. Anderson, R. Barbour, G.S. Basi, R. Caccavello, D. Davis, M. Doan, H.F. Dovey, 654 
N. Frigon, J. Hong, K. Jacobson-Croak, N. Jewett, P. Keim, J. Knops, I. Lieberburg, M. 655 
Power, H. Tan, G. Tatsuno, J. Tung, D. Schenk, P. Seubert, S.M. Suomensaari, S. Wang, 656 
D. Walker, J. Zhao, L. McConlogue, V. John, Purification and cloning of amyloid precursor 657 
protein beta-secretase from human brain, Nature 402 (1999) 537-40. 658 
[21] S.J. Patey, E.A. Edwards, E.A. Yates, J.E. Turnbull, Heparin derivatives as inhibitors of 659 
BACE-1, the Alzheimer's beta-secretase, with reduced activity against factor Xa and 660 
other proteases, J Med Chem 49 (2006) 6129-32. 661 
[22] A.K. Ghosh, D. Shin, D. Downs, G. Koelsch, X. Lin, J. Ermolieff, J. Tang, Design of Potent 662 
Inhibitors for Human Brain Memapsin 2 (beta-Secretase), J Am Chem Soc 122 (2000) 663 
3522-3523. 664 
[23] J. Hu, C.L. Cwi, D.L. Smiley, D. Timm, J.A. Erickson, J.E. McGee, H.C. Yang, D. Mendel, P.C. 665 
May, M. Shapiro, J.R. McCarthy, Design and synthesis of statine-containing BACE 666 
inhibitors, Bioorg Med Chem Lett 13 (2003) 4335-9. 667 
[24] J.S. Tung, D.L. Davis, J.P. Anderson, D.E. Walker, S. Mamo, N. Jewett, R.K. Hom, S. Sinha, 668 
E.D. Thorsett, V. John, Design of substrate-based inhibitors of human beta-secretase, J 669 
Med Chem 45 (2002) 259-62. 670 
[25] M. Citron, T. Oltersdorf, C. Haass, L. McConlogue, A.Y. Hung, P. Seubert, C. Vigo-Pelfrey, 671 
I. Lieberburg, D.J. Selkoe, Mutation of the beta-amyloid precursor protein in familial 672 
Alzheimer's disease increases beta-protein production, Nature 360 (1992) 672-4. 673 
[26] A.G. Tomasselli, I. Qahwash, T.L. Emmons, Y. Lu, J.W. Leone, J.M. Lull, K.F. Fok, C.A. 674 
Bannow, C.W. Smith, M.J. Bienkowski, R.L. Heinrikson, R. Yan, Employing a superior 675 
BACE1 cleavage sequence to probe cellular APP processing, J Neurochem 84 (2003) 676 
1006-17. 677 
 26 
[27] M.I. Aguilar, A.W. Purcell, R. Devi, R. Lew, J. Rossjohn, A.I. Smith, P. Perlmutter, Beta-678 
amino acid-containing hybrid peptides--new opportunities in peptidomimetics, Org 679 
Biomol Chem 5 (2007) 2884-90. 680 
[28] M.P. Del Borgo, K. Kulkarni, M.I. Aguilar, Using &beta;-Amino Acids and &beta;-Peptide 681 
Templates to Create Bioactive Ligands and Biomaterials, Curr Pharm Des 23 (2017) 682 
3772-3785. 683 
[29] D.L. Steer, R.A. Lew, P. Perlmutter, A.I. Smith, M.I. Aguilar, Beta-amino acids: versatile 684 
peptidomimetics, Curr Med Chem 9 (2002) 811-22. 685 
[30] M. Willem, A.N. Garratt, B. Novak, M. Citron, S. Kaufmann, A. Rittger, B. DeStrooper, P. 686 
Saftig, C. Birchmeier, C. Haass, Control of peripheral nerve myelination by the beta-687 
secretase BACE1, Science 314 (2006) 664-6. 688 
[31] T. Kimura, D. Shuto, Y. Hamada, N. Igawa, S. Kasai, P. Liu, K. Hidaka, T. Hamada, Y. Hayashi, 689 
Y. Kiso, Design and synthesis of highly active Alzheimer's beta-secretase (BACE1) 690 
inhibitors, KMI-420 and KMI-429, with enhanced chemical stability, Bioorg Med Chem 691 
Lett 15 (2005) 211-5. 692 
[32] F. Wangsell, P. Nordeman, J. Savmarker, R. Emanuelsson, K. Jansson, J. Lindberg, S. 693 
Rosenquist, B. Samuelsson, M. Larhed, Investigation of alpha-phenylnorstatine and 694 
alpha-benzylnorstatine as transition state isostere motifs in the search for new BACE-1 695 
inhibitors, Bioorg Med Chem 19 (2011) 145-55. 696 
[33] D. Clayton, I. Hanchapola, W.G. Thomas, R.E. Widdop, A.I. Smith, P. Perlmutter, M.I. 697 
Aguilar, Structural determinants for binding to angiotensin converting enzyme 2 (ACE2) 698 
and angiotensin receptors 1 and 2, Front Pharmacol 6 (2015) 5. 699 
[34] R.A. Lew, E. Boulos, K.M. Stewart, P. Perlmutter, M.F. Harte, S. Bond, S.B. Reeve, M.U. 700 
Norman, M.J. Lew, M.I. Aguilar, A.I. Smith, Substrate analogs incorporating beta-amino 701 
acids: potential application for peptidase inhibition, FASEB J 15 (2001) 1664-6. 702 
[35] D. Steer, R. Lew, P. Perlmutter, A.I. Smith, M.I. Aguilar, Inhibitors of 703 
metalloendopeptidase EC 3.4.24.15 and EC 3.4.24.16 stabilized against proteolysis by 704 
the incorporation of beta-amino acids, Biochemistry 41 (2002) 10819-26. 705 
[36] H. Cui, A.C. Hung, C. Freeman, C. Narkowicz, G.A. Jacobson, D.H. Small, Size and sulfation 706 
are critical for the effect of heparin on APP processing and Abeta production, J 707 
Neurochem 123 (2012) 447-57. 708 
[37] H. Cui, A.C. Hung, D.W. Klaver, T. Suzuki, C. Freeman, C. Narkowicz, G.A. Jacobson, D.H. 709 
Small, Effects of heparin and enoxaparin on APP processing and Abeta production in 710 
primary cortical neurons from Tg2576 mice, PLoS One 6 (2011) e23007. 711 
 712 
